- Stocks
- Pharma & Healthcare
- Anlon Healthcare
Anlon Healthcare share price
NSE: AHCLPharma & HealthcareDrug Manufacturers - Specialty & Generic
Anlon Healthcare at a glance
Anlon Healthcare (NSE: AHCL) closed at ₹26.92 on 19 Oct 2026, down 0.22% on the day. With a market capitalisation of ₹1,431 Cr, it ranks 1305th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 44.1× trailing earnings, against a return on equity of 25.5% in FY25. Over the past year the share price has risen 108.5%. Its 52-week range is ₹10.37 (2 Mar 2026) to ₹37.24 (30 Sep 2026); the last close is 27.7% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹88 Cr and net profit ₹8 Cr, on a consolidated basis. Promoters held 52.68% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,431 CrRank 1305 on NSE
- P/E (trailing)
- 44.1×
- Price to book
- 0×FY25
- ROE
- 25.5%FY25
- ROCE
- 25.2%FY25
- Debt to equity
- 0.73FY25
- Net profit margin
- 17.1%FY25
- Book value / share
- ₹20.18FY25
- 52-week high
- ₹37.2430 Sep 2026
- 52-week low
- ₹10.372 Mar 2026
- 1-year return
- +108.5%
- RSI (14-day)
- 50.8
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.22% | −8.8% | +22.4% | +79.4% | +108.5% |
Anlon Healthcare quarterly results
| Quarter | Q4 FY25 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|
| Revenue | ₹49 Cr | ₹36 Cr | ₹51 Cr | ₹88 Cr |
| Revenue YoY | — | — | +4.0% | — |
| Net profit | ₹17 Cr | ₹5 Cr | ₹11 Cr | ₹8 Cr |
| Net profit YoY | — | — | −33.5% | — |
| Net margin | 34.0% | 14.5% | 21.8% | 9.5% |
| EPS | ₹5.15 | ₹1.13 | ₹2.33 | ₹0.16 |
Anlon Healthcare financials
| Item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | ₹57 Cr | ₹113 Cr | ₹67 Cr | ₹120 Cr |
| Operating profit | −₹0 Cr | ₹7 Cr | ₹10 Cr | ₹27 Cr |
| Net profit | −₹0 Cr | ₹6 Cr | ₹10 Cr | ₹21 Cr |
| EPS (₹) | −₹0.09 | ₹4.85 | ₹6.68 | ₹6.37 |
| Cash from operations | −₹2 Cr | −₹3 Cr | −₹3 Cr | −₹23 Cr |
| Total debt | ₹52 Cr | ₹58 Cr | ₹54 Cr | ₹38 Cr |
| Shareholders' equity | ₹2 Cr | ₹7 Cr | ₹21 Cr | ₹80 Cr |
Anlon Healthcare shareholding pattern
| Holder | 3 Sep 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|
| Promoters | 52.68% | 52.68% | 52.68% | 52.68% | 52.68% |
| Foreign institutions | 14.42% | 0.00% | 0.23% | 0.32% | 1.67% |
| Domestic institutions | 4.35% | 2.83% | 4.49% | 4.60% | 1.22% |
| Non-institutions | 28.55% | 44.49% | 42.60% | 42.40% | 44.43% |
Anlon Healthcare vs peers
The listed Pharma & Healthcare companies nearest to Anlon Healthcare by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| GKSLGujarat Kidney And Super Speciality | ₹188.00 | +0.40% | — | ₹1,482 Cr | 75.5 | — |
| AMRUTANJANAmrutanjan Health Care | ₹501.00 | −3.09% | −28.8% | ₹1,448 Cr | 25 | — |
| JAGSNPHARMJagsonpal Ser | ₹217.95 | −0.07% | −1.3% | ₹1,435 Cr | 34.5 | — |
| AHCLAnlon Healthcare | ₹26.92 | −0.22% | +108.5% | ₹1,431 Cr | 44.1 | — |
| TTKHLTCARETTK Healthcare | ₹1,007.60 | −2.93% | −12.2% | ₹1,424 Cr | 21.7 | — |
| SHALBYShalby | ₹126.00 | −2.33% | −49.9% | ₹1,361 Cr | 38.9 | — |
| KOPRANKopran | ₹279.00 | +2.01% | +61.2% | ₹1,347 Cr | 52.3 | — |
Ask anything about Anlon Healthcare
Pivot answers on the live chart with evidence you can check, and tests strategies against AHCL's own history. Try: “Why has AHCL moved over the last three months?” · “Backtest a 50-day moving-average crossover on AHCL over five years” · “Compare AHCL with GKSL on margins and valuation”
Frequently asked questions about Anlon Healthcare
What is the share price of Anlon Healthcare today?
Anlon Healthcare (NSE: AHCL) last closed at ₹26.92 on 19 Oct 2026. Its 52-week high is ₹37.24 and its 52-week low is ₹10.37.
What is the market cap of Anlon Healthcare?
Anlon Healthcare's market capitalisation is ₹1,431 Cr (₹1,431 Cr) at the 19 Oct 2026 close, ranking 1305th among the NSE companies Pivot tracks.
What is the P/E ratio of Anlon Healthcare?
Anlon Healthcare trades at a trailing P/E of 44.1. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 38.9.
What is the ROE and ROCE of Anlon Healthcare?
Return on equity was 25.5% in FY25 and return on capital employed was 25.2% in FY25 (standalone figures).
Is Anlon Healthcare a debt-free company?
No. Anlon Healthcare's debt-to-equity ratio was 0.73 in FY25, with total debt of ₹38 Cr.
What were Anlon Healthcare's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Anlon Healthcare reported revenue of ₹88 Cr and net profit of ₹8 Cr.
How has Anlon Healthcare stock performed over the last year?
Anlon Healthcare's share price has risen 108.5% over the past year, +79.4% over three months and +22.4% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Anlon Healthcare?
As of 30 Jun 2026: promoters 52.68%, foreign institutions 1.67%, domestic institutions 1.22%, non-institutions 44.43%.
Who are Anlon Healthcare's competitors?
The listed Pharma & Healthcare companies closest to Anlon Healthcare by market cap are Gujarat Kidney And Super Speciality, Amrutanjan Health Care, Jagsonpal Ser, TTK Healthcare, Shalby and Kopran.
Is Anlon Healthcare a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Anlon Healthcare's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AHCL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text